Dr Melvin Chua is a Clinician-Scientist at the National Cancer Centre Singapore, and Principal Investigator of the Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Beam Therapy – Precision Radiation Oncology Programme, Division of Radiation Oncology. His research is supported by the NMRC Clinician-scientist award, and is focused on discovery and translational cancer genomics, and the development of biomarker-directed clinical trials in nasopharyngeal (NPC) and prostate cancers.
He graduated from the Yong Loo Lin School of Medicine, National University Singapore in 2002. He obtained his Fellowship in Clinical Oncology from the Royal College of Radiologists, and his Doctorate from the University College London in 2013. He later completed post-doctoral Clinician-scientist fellowships at the Mount Vernon Cancer Centre, UK, and the Princess Margaret Cancer Center, Toronto.
Dr Chua is a KOL on NPC and prostate cancer, and he has been invited to speak at >100 international meetings. He is also on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network and a board member on the Head Neck Cancer International Group (HNCIG).
His other academic activities include his roles as the Associate Senior Editor of the International Journal of Radiation Oncology Biology Physics – Official journal of the American Society of Radiation Oncology and Editor-in-Chief, Annals of Nasopharynx Cancer. He also serves on the International Education Steering Group and the Asia-Pacific Regional Council of the American Society of Clinical Oncology (ASCO). He has published over 80 peer-reviewed papers, with a H-index of 22, including highly cited articles in the New England Journal of Medicine, Lancet, Nature, Cell, Journal of Clinical Oncology and JAMA Oncology.
Abstracts this author is presenting: